Modified IL-7 Fusion Protein Formulation for Stress-Induced Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations for modified IL-7 fusion proteins are unstable and prone to aggregation due to structural and physiochemical degradation, particularly when the Fc region is used as a fusion partner, necessitating a stabilized formulation to enhance stability for pharmaceutical use.
Innovation Solution
A pharmaceutical formulation comprising a modified IL-7 fusion protein with a basal buffer concentration of 10 to 50 mM, a sugar concentration of 2.5 to 5 w/v %, and a surfactant concentration of 0.05 to 6 w/v % is developed to maintain stability under stress conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a modified IL-7 fusion protein is prepared for pharmaceutical use, then immune therapeutic effect is improved, but protein stability deteriorates leading to aggregation and degradation
Solution Approach 1:
The patent applies parameter changes by optimizing formulation conditions including pH (6.0-8.0), ionic strength, and temperature to enhance protein stability. Specific buffers (phosphate, HEPES, Tris) at controlled concentrations are used to maintain optimal physicochemical parameters that prevent aggregation and degradation of the IL-7 fusion protein
Solution Approach 2:
The patent uses stabilizing agents as intermediaries between the protein and degrading environment. These include sugars (sucrose, trehalose), amino acids (glycine, arginine), and surfactants (Tween 20, Tween 80) that act as protective mediators to prevent direct interaction between the protein and harmful factors causing aggregation or degradation
2Duration of action of moving object
If Fc region is used as fusion partner to enhance half-life, then pharmacokinetic properties are improved, but physiochemical stability deteriorates due to large molecular weight and complex structure
Solution Approach 1:
The patent addresses the stability issue of Fc-fusion proteins by carefully controlling formulation parameters such as pH (optimized to 6.0-8.0 range) and ionic strength. The use of specific buffers and controlled protein concentration (1-100 mg/mL) helps manage the complex physicochemical behavior of large Fc-containing molecules, preventing aggregation while maintaining extended half-life
Solution Approach 2:
The patent employs composite formulation systems combining multiple stabilizing components (buffers, sugars, amino acids, surfactants) to collectively stabilize the complex Fc-fusion protein structure. This multi-component approach addresses the stability challenges posed by the large molecular weight and complex structure while preserving the pharmacokinetic benefits
Data Source
AI summary
Provided is a pharmaceutical formulation comprising a modified IL-7 protein. More particularly, it comprises (a) a modified IL-7 fusion protein; (b) a basal buffer with a concentration of 10 to 50 mM; (c) a sugar with a concentration of 2.5 to 5w/v %; and (d) a surfactant with a concentration of 0.05 to 6w/v %.Such pharmaceutical formulation of a modified IL-7 fusion protein does not show aggregates formation, but shows protective effects on proteins under stress conditions such as oxidation or agitation, and thus can effectively be used for the treatment of a patient.